Yazgan S. | Celik U. | Ayar O. | Ugurbas S.H. | Celik B. | Akdemir M.O. | Ugurbas S.C.

Article | 2018 | International Ophthalmology38 ( 1 ) , pp.43 - 52

Purpose: To compare the systemic and ocular characteristics and laboratory findings of patients developing toxic anterior segment syndrome (TASS) after uneventful phaco surgery with unaffected subjects undergoing the same surgery in the same session. Design: A retrospective case–control study. Methods: The study group consisted of 26 eyes of 26 patients who underwent uneventful phaco surgery and who went on to develop TASS, while the control group included 39 subjects who had routine phaco surgery in the same session by the same surgeon. The sterilization stages of reusable instruments, disposable instruments, and compositions were . . .recorded. The preoperative systemic diseases, complete blood count parameters, glycosylated hemoglobin (HbA1c), biochemical parameters, thyroid hormone profiles, and the surgical features were compared between the two groups. Results: Type 2 diabetes mellitus (DM), systemic hypertension (HT), hyperlipidemia, chronic ischaemic heart disease, and chronic renal failure were significantly more common in the TASS group (p Daha fazlası Daha az

Yazgan S. | Arpaci D. | Celik H.U. | Isik I.

Article | 2018 | International Ophthalmology38 ( 2 ) , pp.617 - 625

Purpose: To evaluate macular volume, retinal nerve fiber layer, and macular and peripapillary choroidal thickness in acromegaly patients. Method: In this prospective, case–control study, 31 patients with acromegaly and 32 healthy subjects were recruited. Only right eyes were evaluated. Macular choroidal thickness (CT) was measured at three points, peripapillary CT was measured at eight points, and macular volume was measured at nine areas in the central 6 mm circle zone by spectraldomain optical coherence tomography (OCT). Retinal nerve fiber layer (RNFL) was measured automatically at six segments by OCT. Results: The mean macular a . . .nd peripapillary CT at all measuring points were significantly higher in acromegaly group (p Daha fazlası Daha az

Kaldırım H.E. | Yazgan S.

Article | 2018 | International Ophthalmology38 ( 4 ) , pp.1549 - 1558

Purpose: To compare the efficacy of intravitreal injection of ranibizumab, dexamethasone implant and aflibercept for the management of macular edema (ME) related to branch retinal vein occlusion (BRVO). Methods: This retrospective and comparative study included 62 eyes of 62 patients with BRVO and ME. Patients received one of the following treatments: 0.5 mg ranibizumab (group 1, n = 22), 0.7 mg dexamethasone implant (group 2, n = 20) and 2 mg aflibercept (group 3, n = 20). The 6-month treatment protocol in groups 1 and 3 consisted of 3-dose loading treatment for the first 3 months and followed by repeat injections based on clinical . . . necessity. Group 2 received only single dose of 0.7 mg dexamethasone implant for 6 months. Visual acuity (VA), central macular thickness (CMT), serous retinal detachment (SRD) height and intraocular pressure (IOP) measurements were done at baseline and first 6 months of follow-up. Results: At baseline, the groups did not differ in age, gender, duration of ME, VA, CMT, IOP and SRD height (p > 0.05). Mean number of injections per eye within six months were 3.64 ± 0.49 (range 3–4) in group 1, only 1 in group 2 and 3.35 ± 0.49 (range 3–4) in group 3.VA was significantly better in group 2 in first 3 months but it became the worst among three groups in sixth month. CMT did not differ between groups in first 3 months, but it was significantly higher in group 2 at sixth month. SRD height was significantly lower in group 2 in first 3 months, but there was no difference between the groups at the end of the sixth month. IOP was significantly higher in group 2 in third and sixth months. Conclusion: In the treatment of ME associated with BRVO, dexamethasone implant appears to be more advantageous in terms of VA and SRD height for the first 3 months. However, at the end of the sixth month of treatment, anti-VEGF drugs were more efficient in maintaining the increased visual acuity and reduced CMT. A dexamethasone implant may be the first treatment option in BRVO cases with high SRD. © 2017, Springer Science+Business Media B.V Daha fazlası Daha az